The Role of Platelet Activating Factor and the Efficacy of Apafant Ophthalmic Solution in Experimental Allergic Conjunctivitis
| Autor: | Masatomo Kato, Tatsuji Kurose, Tomoko Oda, Suguru Miyaji |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Male
Allergy Time Factors Conjunctiva Guinea Pigs medicine.disease_cause Capillary Permeability chemistry.chemical_compound Edema Animals Humans Medicine Pharmacology (medical) Antigens Ketotifen Platelet Activating Factor Conjunctivitis Allergic Pharmacology Dose-Response Relationship Drug Platelet-activating factor business.industry Pruritus Dye Dilution Technique Immunization Passive Azepines Triazoles medicine.disease Allergic conjunctivitis Disease Models Animal Ophthalmology medicine.anatomical_structure chemistry Allergic response Immunology Conjunctival sac lipids (amino acids peptides and proteins) Ophthalmic Solutions medicine.symptom business Anaphylaxis |
| Zdroj: | Journal of Ocular Pharmacology and Therapeutics. 19:315-324 |
| ISSN: | 1557-7732 1080-7683 |
| DOI: | 10.1089/108076803322279372 |
| Popis: | Platelet-activating factor (PAF) may be an important mediator in allergic conjunctivitis. In this study, apafant, a potent PAF antagonist, was evaluated for topical ocular anti-PAF activity in PAF and antigen stimulated conjunctivitis models. PAF, when injected into parpebral conjunctiva, provoked an acute increase, measured as dye leakage, in conjunctival vascular permeability. Apafant inhibited this response in a dose-related manner, and the inhibitory action of 0.1% apafant lasted for at least 6 hours duration. PAF, when instilled into the conjunctival sac, induced itch-scratching behavior and clinical symptoms, such as conjunctival redness and edema. These were inhibited by pretreatment with apafant ophthalmic solution. In a passive conjunctival anaphylaxis model in guinea pigs, significant inhibition of the allergic response was observed following topical ocular administration of apafant 5 and 15 minutes prior to the antigen challenge. We have demonstrated that PAF plays an important role in the development of allergic conjunctivitis. These results clearly indicate that apafant has potential as a topical ocular anti-PAF for treating allergic conjunctivitis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|